AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Eyenovia Inc. (EYEN)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.05

-0.01 (-14.38%)

At close: Jan 28, 2025, 2:53 PM

undefined% (undefined)

Bid	0.05
Market Cap	5.97M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.69
PE Ratio (ttm)	-0.08
Forward PE	n/a
Analyst	Hold

Ask	0.05
Volume	8,492,316
Avg. Volume (20D)	26,063,361
Open	0.05
Previous Close	0.06
Day's Range	0.05 - 0.06
52-Week Range	0.05 - 2.57
Beta	undefined

About EYEN

Eyenovia, Inc., a clinical stage ophthalmic company, engages in developing therapeutics based on its proprietary microdose array print platform technology. The company focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. It focuses on the development of therapeutic indications for patients with progressive myopia and age-related near vision impair...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jan 25, 2018

Employees 57

Stock Exchange NASDAQ

Ticker Symbol EYEN

Website https://www.eyenovia.com

Analyst Forecast

According to 4 analyst ratings, the average rating for EYEN stock is "Hold." The 12-month stock price forecast is $2, which is an increase of 3631.34% from the latest price.

Buy 0.00%

Hold 100.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Eyenovia Inc. is scheduled to release its earnings on Mar 17, 2025, during market hours.
Analysts project revenue of $1.60M, reflecting a 61.70K% YoY growth and earnings per share of -0.1, making a -44.44% decrease YoY.

Why Price Moved

1 week ago

-23.37%

Eyenovia shares are trading lower after the compan... Unlock content with Pro Subscription

2 months ago

-70.04%

Eyenovia shares are trading lower after the company announced that its CHAPERONE trial is not meeting its primary endpoint, prompting the discontinuation of the study and a review of the full data set to evaluate next steps for the program.

News

2 months ago · zacks.com

Eyenovia Stock Tumbles on Termination of Phase III Myopia Study

EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.

2 months ago · benzinga.com

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet ...

2 months ago · reuters.com

Eyenovia to discontinue late-stage study for eye drug

Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal.

2 months ago · seekingalpha.com

Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript

Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Pa...

2 months ago · zacks.com

Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates

Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.18 per share a year ago.